Compare GPRE & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | SDGR |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 856.7M |
| IPO Year | 2004 | 2020 |
| Metric | GPRE | SDGR |
|---|---|---|
| Price | $13.65 | $12.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $10.61 | ★ $24.33 |
| AVG Volume (30 Days) | 1.6M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,091,680,000.00 | $255,869,000.00 |
| Revenue This Year | N/A | $23.92 |
| Revenue Next Year | $11.85 | $19.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $3.14 | $11.11 |
| 52 Week High | $15.64 | $27.63 |
| Indicator | GPRE | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 38.84 |
| Support Level | $9.25 | N/A |
| Resistance Level | $15.64 | $19.51 |
| Average True Range (ATR) | 0.73 | 0.71 |
| MACD | -0.10 | 0.19 |
| Stochastic Oscillator | 21.03 | 30.74 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.